ABCELLERA BIOLOGICS Net Asset Quality Index
ABCELLERA BIOLOGICS net asset quality index. ABCELLERA BIOLOGICS (8QQ) has a Net Asset Quality Index of 68.5% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €1.31 Billion minus total liabilities of €411.56 Million yields net assets of €896.02 Million. A higher index indicates a stronger, lower-leverage balance sheet. See ABCELLERA BIOLOGICS (8QQ) shareholders funds for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of ABCELLERA BIOLOGICS (2021–2025)
Net asset quality index of ABCELLERA BIOLOGICS from 2021 to 2025. This chart shows how ABCELLERA BIOLOGICS's Net Asset Quality Index has evolved across 5 annual periods from 2021 to 2025. As of June 2026, the index stands at 68.5%, representing net assets of €896.02 Million against total assets of €1.31 Billion EUR. Check 8QQ capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
ABCELLERA BIOLOGICS Net Asset Quality Index by Year (2021–2025)
ABCELLERA BIOLOGICS net asset quality index by year from 2021 to 2025. The table below presents the year-by-year Net Asset Quality Index for ABCELLERA BIOLOGICS from 2021 to 2025, covering 5 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see ABCELLERA BIOLOGICS (8QQ) total market value.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 71.3% | €966.90 Million | €1.36 Billion | €390.05 Million | ▼ -6.4 pp |
| 2024 | 77.6% | €1.06 Billion | €1.36 Billion | €304.47 Million | ▲ +0.2 pp |
| 2023 | 77.4% | €1.15 Billion | €1.49 Billion | €335.78 Million | ▼ -2.6 pp |
| 2022 | 80.0% | €1.23 Billion | €1.54 Billion | €307.63 Million | ▲ +2.2 pp |
| 2021 | 77.8% | €1.03 Billion | €1.32 Billion | €292.84 Million | — |